Biogen and Pfizer

Selected news for the company - Biogen, and the company - Pfizer. We have 642 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/6/2022 More top hospitals aren't offering Biogen Alzheimer's drug - STAT STAT Pharmalot Pharmalittle: More top hospitals aren‚Aot offering Biogen Alzheimer‚Aos drug; Pfizer may lower Covid pill price in poor countries until supplies rise By Ed SilvermanAlex Hogan/STATH ello, everyone, and how are you today? Cloudy skies are hovering this morning over the Pharmalot campus, where the official mascot awaits a play date and the short person is, once again, sleeping in. As for us, we are ...
12/17/2021 Global and China Glanzmann Thrombasthenia Therapeutic Drug Market Size, Status and Forecast 2021-2027 ... Biogen- Bioverativ (Sanofi)- Bayer- CSL Behring- Grifols- Bristol-Myers Squibb- PfizerTable of Contents1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Glanzmann Thrombasthenia Therapeutic Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 20271.2.2 Platelet Transfusion1.2.3 Recombinant Activated Factor VII1.2.4 Antifibrinolytics1.2.5 Fibrin Sealants1.2.6 Thrombin1.2.7 Desmopressin1.3 Market by Application1.3.1 Global Glanzmann Thrombasthenia Therapeutic Drug Market ...
12/13/2021 Global Multiple Sclerosis Drugs Market Research Report 2021 Featuring Biogen, Novartis, Roche, Bayer HealthCare, Pfizer., Merck & Co, Sanofi, Teva Pharm, GSK and Acorda Therapeutics - ResearchAndMarkets.com Business Wire ... Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline and Acorda Therapeutics Inc.The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions. It is ...
11/30/2021 Psoriasis Drugs Industry Research Report is Projected to Grow at a CAGR of 9.3% during the forecast period 2021-2024. ... Pfizer Inc.‚Ai Johnson and Johnson (Janssen Biotech Inc.)‚Ai Celgene Corporation‚Ai Takeda Pharmaceutical Company Limited‚Ai Stiefel Laboratories Inc.‚Ai Novartis AG‚Ai Amgen Inc.‚Ai Biogen Idec‚Ai AbbVie Inc.Scope: ‚AiPsoriasis is a genetic condition which may not be present at birth. This genetic condition may also be triggered by certain environmental and genetic factors. Factors such as the changing lifestyles of people are leading ...
10/19/2021 Royalty Pharma (NASDAQ:RPRX) Downgraded by Zacks Investment Research Royalty Pharma (NASDAQ:RPRX) was downgraded by Zacks Investment Research from a ‚Aubuy‚Au rating to a ‚Auhold‚Au rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.According to Zacks, ‚AuRoyalty Pharma plc is a funder of biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead ...
10/8/2021 Inflammatory Bowel Disease Drugs Market | Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2020-2026 ... Biogen Idec, Merck, Mitsubishi Tanabe, Boehringer Ingelheim, Janssen Pharmaceuticals, Akebia Therapeutics, Shire, Pfizer, Genentech, Novartis, UCB, Galapagos, AmgenGet Sample PDF Copy (Including Table of Contents, Tables, and Figures) @ https://garnerinsights.com/Global-Inflammatory-Bowel-Disease-Drugs-Market-Report-2020-by-Key-Players-Types-Applications-Countries-Market-Size-Forecast-to-2026-Based-on-2020-COVID-19-Worldwide-Spread request-sampleOn the basis of types, the Inflammatory Bowel Disease Drugs market ...
10/8/2021 Biosimilars Market: 3 Bold Projections for 2021 | Pfizer, Novartis, Biocon, Biogen The ‚Au Worldwide Biosimilars ‚Ai Market Development Scenario ‚Au Study has been added to HTF MI database. The study covers in-depth overview, description about the Product, Industry Scope and elaborates market outlook and growth status to 2027. At present, the market is developing its presence following current economic slowdown and its Impact. Some of the key players considered in the study are Pfizer, Novartis, Biocon, Biogen, Fresenius Kabi AG ...
10/8/2021 Orphan Drugs Market Industry Outlook, Opportunities 2026, Report Forecast By Capital Investment, Trends ... Biogen Inc., Johnson & Johnson, Amgen Inc., AstraZeneca plc., Bayer AG, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., Novo Nordisk A/S, Merck & Co. Inc., and Celgene Corporation. Major focus of the research study is on detailed study of the major growth drivers and restrains and their exact influence on the fluctuating growth of the global Orphan Drugs portrayed in the report. The drivers studied justify the potential growth ...
10/7/2021 Global Orphan Drugs Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com Business Wire ... Biogen Inc. - Bristol-Myers Squibb Company - F. Hoffmann-La Roche AG (Roche Holding AG) - Jazz Pharmaceuticals PLC - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pfizer Inc. - Sanofi S.A. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Ltd. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as ...
10/7/2021 Recent Analysts‚Äô Ratings Updates for Royalty Pharma (RPRX) - Ticker Report Ticker Report A number of research firms have changed their ratings and price targets for Royalty Pharma (NASDAQ: RPRX):9/29/2021 ‚Ai Royalty Pharma was downgraded by analysts at from a ‚Aubuy‚Au rating to a ‚Auhold‚Au rating. According to Zacks, ‚AuRoyalty Pharma plc is a funder of biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen ...
9/29/2021 Dassault Aviation (OTCMKTS:DUAVF) Shares to Split on Friday, October 1st | Daily Political Daily Political ... Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao Promacta and Vertex‚Aos Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. ‚AuA number of other brokerages also recently commented on RPRX. Tigress Financial began coverage on shares of Royalty Pharma in a research report on Friday, July 30th. They set a buy rating and a ...
9/25/2021 Royalty Pharma (NASDAQ:RPRX) Raised to ‚ÄúBuy‚Äù at Zacks Investment Research ... Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia, Novartis‚Ao Promacta and Vertex‚Aos Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. ‚Au A number of other analysts have also issued reports on the company. Tigress Financial began coverage on Royalty Pharma in a research note on Friday, July 30th. They issued a buy rating and ...
9/25/2021 Royalty Pharma (NASDAQ:RPRX) Downgraded by Zacks Investment Research Zacks Investment Research cut shares of Royalty Pharma (NASDAQ:RPRX) from a buy rating to a hold rating in a report released on Wednesday morning, Zacks.com reports. According to Zacks, ‚AuRoyalty Pharma plc is a funder of biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia ...
9/23/2021 Biosimilars Market by Application and Geography | Global Forecast to 2025 | 17,000+ Technavio Research Reports ... Biogen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Merck and Co. Inc., Novartis AG, Pfizer Inc., and Viatris Inc. are some of the major market participants. Although the price advantage of biosimilars over biologics will offer immense growth opportunities, market access barriers for biosimilars will challenge the growth of the market participants. To make the most of the opportunities, market ...
9/18/2021 U.S. FDA advisors reject COVID-19 booster shot approval, but may vote for older adults ... for Americans age 16 and older, potentially undermining the Biden administration‚Aos plan to roll out third shots of the Pfizer/BioNTech vaccine as soon as next week. But there was widespread support among panelists ... can reject the advice as it did recently in approving Biogen Inc‚Aos controversial Alzheimer‚Aos drug Many committee members were critical of the booster plan, arguing that the data presented by Pfizer and the ...
9/17/2021 U.S. FDA advisers may vote on COVID-19 boosters for older adults after rejecting broad approval - Netscape News ... boosters for Americans age 16 and older, potentially undermining the Biden administration's plan to roll out third shots of the Pfizer/BioNTech vaccine as soon as next week.But there was widespread support among panelists ... can reject the advice as it did recently in approving Biogen Inc's controversial Alzheimer's drugMany committee members were critical of the booster plan, arguing that the data presented by Pfizer and the FDA was ...
9/17/2021 UPDATE 5-U.S. FDA advisers may vote on COVID-19 boosters for older adults after rejecting broad approval - Netscape News ... boosters for Americans age 16 and older, potentially undermining the Biden administration's plan to roll out third shots of the Pfizer/BioNTech vaccine as soon as next week.But there was widespread support among panelists ... can reject the advice as it did recently in approving Biogen Inc's controversial Alzheimer's drugMany committee members were critical of the booster plan, arguing that the data presented by Pfizer and the FDA was ...
9/17/2021 U.S. FDA advisers may vote on COVID-19 boosters for older adults after rejecting broad approval - Netscape News ... boosters for Americans age 16 and older, potentially undermining the Biden administration's plan to roll out third shots of the Pfizer/BioNTech vaccine as soon as next week.But there was widespread support among panelists ... can reject the advice as it did recently in approving Biogen Inc's controversial Alzheimer's drugMany committee members were critical of the booster plan, arguing that the data presented by Pfizer and the FDA was ...
9/17/2021 U.S. FDA advisers may vote on COVID-19 boosters for older adults after rejecting broad approval ... for Americans age 16 and older, potentially undermining the Biden administration‚Aos plan to roll out third shots of the Pfizer/BioNTech vaccine as soon as next week. But there was widespread support among panelists ... can reject the advice as it did recently in approving Biogen Inc‚Aos controversial Alzheimer‚Aos drug Many committee members were critical of the booster plan, arguing that the data presented by Pfizer and the ...
9/17/2021 U.S. FDA vaccine advisers vote against COVID-19 booster shot approval - Netscape News ... Pfizer/BioNTech vaccine as soon as next week.The FDA will take the panel's recommendation into consideration in making its decision on the boosters. But it can reject the advice as it did recently in approving Biogen Inc's controversial Alzheimer's drugMany committee members were critical of the booster plan, arguing that the data presented by Pfizer and the FDA is incomplete and that the request for approval for people ...
9/16/2021 Royalty Pharma (NASDAQ:RPRX) Stock Rating Lowered by Zacks Investment Research Zacks Investment Research downgraded shares of Royalty Pharma (NASDAQ:RPRX) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports.According to Zacks, ‚AuRoyalty Pharma plc is a funder of biopharmaceutical industry. The compnay‚Aos portfolio includes royalties on commercial products, including AbbVie and J&J‚Aos Imbruvica, Astellas and Pfizer‚Aos Xtandi, Biogen‚Aos Tysabri, Gilead‚Aos HIV franchise, Merck‚Aos Januvia ...
9/13/2021 From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year This year has already witnessed a handful of memorable FDA approvals. And if one thing‚Aos clear, the pandemic hasn‚Aot slowed biopharma‚Aos ability to push prospects over the agency‚Aos finish line. There‚Aos been Biogen‚Aos historic and controversial accelerated approval for Aduhelm in Alzheimer‚Aos disease. That‚Aos not to mention Amgen ...
9/10/2021 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market-Industry Analysis, Share Size, Statistics, Demand, Revenue, Top Companies and Forecast 2020 to 2026 ... Pfizer Inc., CSL, GeNeuro SA, Momenta Pharmaceuticals, Teijin Pharma Limited., ImmuPharma PLC, UCB S.A., Protagen, AstraZeneca, F. Hoffmann-La Roche Ltd, Biogen International, Gliknik Inc., Creative Diagnostics, Novartis AG, Kedrion S.p.A., Octapharma, argenx among others. Global chronic inflammatory demyelinating polyneuropathy (CIDP) market is set to witness a substantial CAGR of 6.45% in the forecast period of 2019- 2026.The report contains data of the base year 2018 and historic year ...
9/1/2021 Mental Illnesses Market Size, Share, Growth & Lucrative Segments Breakdown Global Growth to See Commanding Position in Near Future | Teva Pharmaceutical, Xenon, Biogen, ICAGEN, INC, Pfizer ... Biogen, ICAGEN, INC, Pfizer Inc, Zydus Cadila, ANI Pharmaceuticals, Inc, Novel Laboratories Inc, Norvartis AG, Amneal Pharmaceuticals LLC, ALLERGAN, Bausch Health, Akorn, Incorporated, INDOCO REMEDIES LTD, Somerset Therapeutics, LLC, Galderma Laboratories, L.P. Acorda Therapeutics, Inc and others For More Info, Get Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-mental-illnesses-market Market Definition: Mental illness additionally referred to as mental state disorders, refers to a good vary of ...
8/31/2021 Worldwide Human Coagulation Factor IX Industry to 2026 - by Manufacturers, Regions, Technology, Application and Product Type - ResearchAndMarkets.com Business Wire ... Biogen - Octapharma - Baxter - Bayer - CSL - Novo Nordisk - Greencross - Kedrion - BPL - Hualan Bio - RAAS - Pfizer For the competitor segment, the report includes global key players of Human Coagulation Factor IX as well as some small players. The information for each competitor includes: - Company Profile - Main Business Information - SWOT Analysis - Sales Volume, Revenue, Price and Gross Margin - Market Share Applications Segment: - Hospital - Personal Clinic - Others Types Segment: - AHGB - AHFB - Others Key Topics ...